Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Ruxolitinib Shows Stronger Response in Primary Than Secondary HLH,
15+ hour, 18+ min ago (632+ words) Hemophagocytic lymphohistiocytosis is one of the most feared syndromes in medicine, a runaway immune firestorm in which the body’s own scavenger cells turn against blood cells and organs, and it can kill within weeks if untreated....
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400MM
4+ day, 22+ hour ago (285+ words) ABF Journal Intellia Therapeutics, a biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a global healthcare investment firm The transaction provides Intellia…...
New grant funds study of California’s traditional health care practices
1+ week, 7+ hour ago (608+ words) A landmark effort to bring Indigenous healing practices into the formal health care system is about to face its most rigorous scientific scrutiny yet....
Cellectis Announces Participation in Upcoming Investor Conferences
1+ week, 4+ day ago (115+ words) NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor…...
Cibus Reports Second Quarter Financial Results and Provides Business Update
4+ week, 2+ day ago (283+ words) United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly net cash usage declined 19% sequentially and 31% year over year SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company…...
CGTCON 2026: Join the 11th International Cell & Gene Therapy Conference - CMC Vellore & BRIC-inStem Collab
1+ mon, 1+ week ago (42+ words) 9-10 October 2026 at CMC Vellore Register Now at www.cscrcgt.com Early bird registration is open now. Please find more details and register at Early bird registration is now open. Please find more details and register at www.cscrcgt.com...
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 | INN
1+ mon, 1+ week ago (139+ words) Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 Investing News Network Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 Lineage Cell Therapeutics, Inc. (NYSE American and…...
Cellectis Q2 Results: Financials due August 6 after close
1+ mon, 1+ week ago (600+ words) Cellectis (NASDAQ: CLLS) will report its financial results for the second quarter of 2026, ending June 30, 2026, on Thursday, August 6, 2026. The announcement is scheduled for release after the close of the US market. This disclosure provides investors with an update on the…...
Simris Group appoints biotechnology expert Dr. Tiffany J. Vora as strategic advisor
1+ mon, 2+ week ago (363+ words) Manufacturing Chemist Dr. Vora is a biotechnology scientist, entrepreneur, educator and advisor with experience across molecular biology, genomics, biotechnology innovation and drug discovery. Through her work with technology companies, startups, scientific organizations and the broader innovation ecosystem, she has developed…...
X-Linked Retinoschisis Market Looks Promising With First-Ever Gene Therapies Near The Finish Line, Reveals New Thelansis Report
1+ mon, 2+ week ago (86+ words) X-Linked Retinoschisis Market Looks Promising With First-Ever openPR.com X-Linked Retinoschisis Market Looks Promising With First-Ever Gene Therapies Near The Finish Line, Reveals New Thelansis Report Press release from: THELANSIS KNOWLEDGE PARTNERS LLP X-Linked Retinoschisis (XLRS) Market Outlook, Epidemiology, Competitive…...